0001703057-26-000028
SEC filingRevenue nearly doubled to $8.3M from $4.2M amid partner program progress, narrowing operating and net losses through cost discipline following a legal settlement, though cash burn accelerated on clinical investments.
Revenue rose 96% year-over-year to $8.3 million in Q1 FY2026 from $4.2 million, driven by research fees timing and advancement in partner programs. This growth reflects AbCellera's engine of antibody discovery partnerships, providing a stable revenue base amid the shift toward internal pipeline execution.
Operating loss improved to -$57.5 million from -$62.7 million, an 8% narrowing, primarily due to a legal settlement in December 2025 that reduced legal fees incurred in the period. Compensation expenses also decreased as part of continued headcount optimization aligned with the internal pipeline focus. These measures demonstrate disciplined cost management post-settlement, partially offsetting other pressures. However, expenses increased due to the commencement of depreciation on the clinical manufacturing facility placed in service in December 2025, underscoring the transition from platform buildout to utilization in drug development.
Net loss narrowed to -$43.2 million from -$45.6 million, with diluted EPS improving to -$0.14 from -$0.15. The operating margin remained deeply negative at -692%, typical for a preclinical biotech investing heavily in R&D, but the year-over-year loss improvement signals progress in cost efficiency without sacrificing strategic momentum.
Cash from operating activities reflected increased use of -$33.5 million versus -$11.6 million prior year, driven by working capital timing and the absence of non-recurring upfronts from the comparison period. Free cash flow was -$37.4 million after $3.8 million in capital expenditures, which declined from $10.6 million as major investments in clinical manufacturing and headquarters neared completion. Management notes that with these large platform investments finished, investing cash outflows are expected to reduce, allowing capital reallocation from building capabilities to deploying them in the internal pipeline strategy. This pivot, coupled with headcount optimization, aims to maximize long-term value while navigating drug development risks, including global supply chain disruptions and heightened operational costs.
Overall, Q1 results highlight revenue momentum from partnerships funding the internal shift, with loss narrowing through SG&A discipline post-legal settlement and capex tapering. Investors should note the ongoing cash burn supports continued R&D and pipeline advancement, though additional capital may be required for sustained operations per risk disclosures.